Alexander Senetar, DO
Vascular Neurology · Sarasota, FLNPI 1457856320
Payments from drug & device makers
What this record shows
This record is dominated by grants: $40,000 of the $41,685 with a category attached, or 96.0%. Medtronic accounts for 96.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $40,000 and has fallen 98.2% since, to $702 in 2025. Among vascular neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $1263.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$40K
- Penumbra, Inc.$614
- AstraZeneca$148
- Boston Scientific$140
- Silk Road Medical, Inc.$113
- Catalyst Pharmaceuticals, Inc.$90
- plus $524 from 12 others
What the payments were for
- Grants$40,00096%
- Food & beverage$1,6854%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $40,055 |
| Penumbra, Inc. | 4 | $614 |
| AstraZeneca(2 entities) | 2 | $148 |
| Boston Scientific | 1 | $140 |
| Silk Road Medical, Inc. | 1 | $113 |
| Catalyst Pharmaceuticals, Inc. | 2 | $90 |
| UCB, Inc. | 3 | $87 |
| GE HealthCare | 3 | $85 |
| AbbVie | 3 | $68 |
| Lundbeck LLC | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Neurocrine Biosciences, Inc. | 1 | $34 |
| CSL Behring | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Neurelis, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Tanabe Pharma America, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,685 in reported general payments places this provider in the 90th percentile of 40 vascular neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 17 | $260 |
| Topiramate | 12 | $219 |
| Atorvastatin Calcium | 18 | $171 |
| Donepezil Hcl | 13 | $147 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Sarasota
- Juan Pauta MartinezSarasota$7K
- Eyad AlmallouhiSarasota$6K
- Vikas GuptaSarasota$3K
- David StoneSarasota$2K
- Maxim MokinTampa$137K
- Robert MannelJacksonville Beach$92K
- Amin AghaebrahimJacksonville$36K
- Miguel ChuquilinTallahassee$30K
- Richard CallisonFort Pierce$28K
- Farah FourcandVero Beach$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.